Premium
FDA approves first drug for postpartum depression treatment
Author(s) -
Canady Valerie A.
Publication year - 2019
Publication title -
mental health weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7583
pISSN - 1058-1103
DOI - 10.1002/mhw.31830
Subject(s) - food and drug administration , medicine , depression (economics) , drug , postpartum depression , drug approval , drug administration , pharmacology , psychiatry , pregnancy , biology , genetics , economics , macroeconomics
The U.S. Food and Drug Administration (FDA) announced March 20 the approval of Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD, a press release stated.